Article Details

Aducanumab rejected in the EU: Biogen to ask EMA to re-examine application - BioPharma Reporter

Retrieved on: 2021-12-20 16:31:37

Tags for this article:

Click the tags to see associated articles and topics

Aducanumab rejected in the EU: Biogen to ask EMA to re-examine application - BioPharma Reporter. View article details on hiswai:

Excerpt

Biogen will ask the European Medicines Agency (EMA) to re-examine its Alzheimer's drug application, following the agency's recommendation to ...

Article found on: www.biopharma-reporter.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up